MRNA - Moderna, Inc.
| Previous Close | 17.90 |
| Open | 18.14 |
| Bid | 18.08 x 800 |
| Ask | 18.11 x 1100 |
| Day's Range | 17.76 - 18.38 |
| 52 Week Range | 11.54 - 29.79 |
| Volume | 25,237,508 |
| Avg. Volume | 2,213,240 |
| Market Cap | 5.966B |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.35 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.56 |
- Simply Wall St.
What Kind Of Investor Owns Most Of Moderna, Inc. (NASDAQ:MRNA)?
The big shareholder groups in Moderna, Inc. (NASDAQ:MRNA) have power over the company. Institutions will often hold...
- Barrons.com
Moderna Wants the Body to Make Its Own Drugs. Analyst Sees Significant Progress.
PiperJaffray analyst raised his price target for stock in the clinical-stage biotech company to $32 from $30.
- Investor's Business Daily
Can The Body Make Its Own Medicine? The Biggest Biotech IPO Says Yes
Moderna stock rocketed in bullish volume Thursday after the biotech company unveiled positive test results for two virus treatments. One is a vaccine. The other helps produce a protein.
- Benzinga
Moderna Aces Early Stage Study Of mRNA Vaccine For Virus Causing Birth Defects
Moderna reported positive data from a three-month interim analysis of safety and immunogenicity data from the Phase 1 study that is evaluating its investigational cytomegalovirus — or CMV — vaccine codenamed mRNA-1647. The company said mRNA-1647 is a vaccine combining six mRNAs in a single vial that encodes for two antigens on the surface of CMV, and it is designed to produce an immune response against the pentamer and gB for the prevention of CMV infection.
- Benzinga
The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) Avedro Inc (NASDAQ: AVDR ) Catalyst Pharmaceuticals ...
- Business Wire
Moderna Announces Positive Phase 1 Results for the First Systemic Messenger RNA Therapeutic Encoding a Secreted Protein (mRNA-1944)
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data in the first analysis of safety and activity in its Phase 1 study evaluating escalating doses of mRNA-1944 administered via intravenous infusion in healthy adults. At all three dose levels, the administration of mRNA-1944 led to detectable levels of CHKV-24 antibody in all participants, ranging from 1 µg/mL to 14 µg/mL.
- Business Wire
Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive data from the three-month interim analysis of safety and immunogenicity of the Phase 1 study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647).
- Motley Fool
3 Biotech Stocks That Could Soar This Week
Investors better get ready for a busy week ahead.
- Barrons.com
Podcast: Why Big Pharma Is Betting on a New Biotech Therapy
Host Alex Eule is joined by Josh Nathan-Kasiz to talk about one of biotech’s most promising treatments, mRNA therapy.
- Business Wire
Moderna Appoints Tracey Franklin as Chief Human Resources Officer
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer.
- Barrons.com
How to Invest in MRNA Technology
Patience--and taking cues from the big pharmaceutical companies--are the keys to making this biotech bet
- Barrons.com
2 Biotech Companies Are Chasing the Next Frontier in Treating Disease. But Will It Work?
Biotechnology companies are working to develop cutting-edge drugs out of messenger RNA, hoping the technology will be able to deliver the benefits of targeted gene therapy with less risk.
- Business Wire
Moderna to Host R&D Day on September 12, 2019
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its third annual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 12 at the JW Marriott Essex House in New York City. Moderna’s R&D Day will include presentations from Stéphane Bancel, chief executive officer, Tal Zaks M.D., Ph.D., chief medical officer and key opinion leaders with a focus on the Company’s clinical development pipeline.
- Business Wire
Moderna to Present at Upcoming Investor Conferences
A replay of each webcast will be archived on Moderna’s website for 30 days following the presentations. Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients.
- Zacks
Moderna (MRNA) Jumps: Stock Rises 5.6%
Moderna (MRNA) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Schaeffer's Investment Research
FDA Nods Fuel Unusual Options Volume on NBRV, MRNA
Call options are running much hotter than usual today
- TheStreet.com
Moderna Stock Surges as FDA Fast Tracks Zika Vaccine
Moderna shares jumped as much as 8.5% on Tuesday, then pulled back, after the biotechnology company said the U.S. Food and Drug Administration granted fast-track designation for its investigational Zika vaccine. The Cambridge, Mass., drug developer said the vaccine, mRNA-1893, is being evaluated in a Phase I study to prevent Zika virus infection in healthy adults. "Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need," Tal Zaks, a physician and the company's chief medical officer, said in a statement.
- Benzinga
The Daily Biotech Pulse: FDA Likes Nabriva's Antibiotic, Snubs Sarepta's DMD Drug; Moderna Gets Fast Track Designation For Zika Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 19) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR ) Avid ...
- MarketWatch
Moderna stock pops after Zika vaccine gets FDA fast track
Shares in Moderna Inc. jumped 7% in extended trading Monday, after the company announced that the Food and Drug Administration had approved its potential vaccine for the Zika virus for a fast track to approval. Zika, a disease spread by mosquitoes, spread in 2016, and many companies are attempting to develop vaccines to the disease. Moderna's attempt at a vaccine is currently in a Phase 1 study, and is being especially targeted to avoiding transmission of the disease from a mother to an unborn child. "Protecting against Zika virus transmission, particularly in women during pregnancy, continues to be an area of high unmet need. Fast Track designation supports our belief in the clinical potential of mRNA-1893 and the importance of developing an effective vaccine that can be rapidly developed and deployed," Chief Medical Officer Tal Zaks said in Monday's announcement. Moderna went public late last year in the biggest initial public offering from a biotechnology company, raising more than $600 million at a valuation of more than $7 billion. Shares have struggled in recent months, closing Monday at $13.40, well short of the $23 price charged in the IPO but still enough for a $4.4 billion market cap.
- Business Wire
Moderna Receives FDA Fast Track Designation for Zika Vaccine mRNA-1893
Moderna, Inc., (MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for its investigational Zika vaccine (mRNA-1893) currently being evaluated in a Phase 1 study for the prevention of Zika virus infection in healthy adults. Fast Track is designed to facilitate the development and expedite the review of therapies and vaccines for serious conditions and fill an unmet medical need.
- American City Business Journals
WeWork joins underperforming Uber, Lyft, Nio as biggest pre-IPO cash guzzlers
All 10 companies on this list of the biggest pre-IPO cash guzzlers are either trading below their first day offering price or are out of business.
Motley FoolModerna, Inc. (MRNA) Q2 2019 Earnings Call Transcript
MRNA earnings call for the period ending June 30, 2019.
- Business Wire
Moderna Provides Business Updates and Reports Second Quarter 2019 Financial Results
Phase 2 Personalized Cancer Vaccine study initiated, with first patient consented
- InvestorPlace
7 Strong Buy Stocks the Street Loves
[Editor's note: "7 Strong Buy Stocks the Street Loves" was previously published in April 2019. It has since been updated to include the most relevant information available.]Which top stocks are Wall Street analysts the most bullish on? I mean stocks with a strong "buy" analyst consensus. These are the stocks that make the most compelling investing opportunities and are definitely worth keeping a close eye on.Using TipRanks powerful stock screener, I set out to pinpoint seven stocks that command the support of the Street. You can customize the screener settings to match your investment strategy. In this case, I selected filters for stocks of all market cap size with a "buy" consensus from analysts and best-performing analysts alike. These are the top analysts with the highest success rate and average return.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHere I specifically select stocks with big upside potential from the current share price. This is based on the upside potential from the current share price to the average analyst price target. * The 10 Best Stocks to Invest in for August Now let's delve into these seven top stocks to buy now: Strong Buy Stocks: Exact Sciences (EXAS)Earlier this year, Exact Sciences Corporation (NASDAQ:EXAS) has just received five back-to-back buy ratings from the Street. These "buys" flooded in following stellar Q4 earnings results. EXAS delivered a solid Q4 revenue beat and raised its 2019 revenue guidance to $710 million-$730 million, above its prior $700 million estimate.Plus the future looks bright for sales of its Cologuard DNA test for colon cancer."EXAS is one of our top picks for 2019, and we reiterate our "buy" rating and our $100 PT," said five-star Canaccord Genuity analyst Mark Massaro. "Exact continues to execute at a high level and isn't afraid to make big investments to hit its ambitious goal of achieving $6 billion of revenue for Cologuard over time."That would give the company over 40% market share for its revolutionary screening product, first launched back in 2014.According to Massaro, even the new revenue guidance is beatable, writing "we see a path to upside to our raised estimates." A similar message comes from Baird's Catherine Ramsey. She writes: "We continue to see the potential for upside… and EXAS remains one of our top ideas."The average analyst price target right now stands at $128.33. Bear in mind shares have surged 87% year-to-date. Want to learn more about Exact Sciences? Get the free EXAS Stock Research Report. OpenText (OTEX)Canadian cloud computing stock Open Text Corp (NASDAQ:OTEX) develops and sells enterprise information management (EIM) software. Essentially, this helps organizations safely manage and share business information.Since the company's inception in 1991, OpenText has deployed around $6 billion capital on acquisitions. Using these acquisitions, OTEX can cement its position as a leader in the EIM space."Our strategy is total growth," said CEO Mark Barrenechea said, "where M&A will continue to be our largest growth driver, augmented with organic growth." So far this strategy appears to be paying off. * The 10 Best Stocks to Invest in for August "We believe OpenText is likely to continue to create shareholder value through its acquisition strategy," RBC analyst Paul Treiber said following the encouraging Q2 numbers,Analysts have a $46.75 average price target on the shares -- over 10% above the current share price. Get the OTEX Stock Research Report. Moderna (MRNA)Moderna (NASDAQ:MRNA) is a pioneer in a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching. No less than eight analysts have published recent buy ratings on the stock.Earlier this year, the company reported positive results from an ongoing phase Ib trial. This is for mRNA-1653, an mRNA-based vaccine for the treatment of human metapneumovirus (HMPV) and parainfluenza virus (PIV3)."The interim phase I data announced today support our outlook for this experimental product and support advancing studies in the pediatric population" said Oppenheimer's Leah R Cann.The mRNA-1653 program is one of Moderna's 21 most current and importantly, one of its 13 focus programs.She points out that currently there are no approved vaccines to prevent hMPV or PIV3 infections, and estimates that worldwide mRNA-1653 sales could reach $1.44 billion by 2030. That's with a predicted launch date of 2024. Get the MRNA Stock Research Report. Nexstar Media (NXST)Following its completion of the Media General acquisition, Nexstar Media Group (NASDAQ:NXST) owns 171 television stations. As the largest TV station operator in the U.S. reaching nearly 39% of households, Nexstar Media Group is a stock worth watching.Analysts certainly seem to think so. Nexstar has received many buy calls in recent months from the Street. Most notably, Evercore ISI's David Joyce upgraded NXST from "hold" to "buy" back in December.Crucially, the company recently acquired many stations. It has agreed to a $6.4 billion deal to buy Tribune's ABC, CBS, FOX, and NBC stations. Tribune shareholders recently approved the deal. What's more, to help avoid any anti-trust issues, Nexstar has announced that it would sell 14 stations. * The 10 Best Stocks to Invest in for August "We assign Nexstar an Outperform rating and a $112 price target. We believe that the Tribune acquisition should create significant value for shareholders," top RBC Capital analyst Leo Kulp tells investors.He ramped up his price target from $96 to $112, adding, "We see limited risk around regulatory approvals…We expect the FCF yield to moderate as the company completes the milestones to closing the deal and de-levers post-closing." Get the NXST Stock Research Report. Boyd Gaming (BYD)Shares in Boyd Gaming Corp (NYSE:BYD) have jumped 34% in 2019 . That's partially thanks to a pretty exceptional Q4 earnings report for the Paradise, Nevada-based casino company."BYD's 4Q18 operating results were nothing short of sensational," said five-star Stifel Nicolaus analyst Steven Wieczynski. "BYD's strong 4Q18 results (were) an exclamation point on a strong 2018, with guidance above expectations serving as the cherry on top."With widespread growth throughout the business, BYD EBITDAR came in at $208.6mm, easily surpassing the estimated $197.1 million. Meanwhile 2019 EBITDAR guidance was established at a healthy $885 million-910 million, the midpoint of which was above Consensus forecasts ahead of the print ($888 million)."Post the strong 4Q18 results and with, we believe BYD is well positioned to continue to show healthy and steady same-store growth, while continuing to integrate its accretive acquisitions from the 2H18," said Deutsche Bank's Carlo Santarelli.That's with a "very compelling" current valuation to boot. With a " buy" analyst consensus, BYD boasts fa $35.60 average price target (25% upside potential). Get the BYD Stock Research Report. LivePerson (LPSN)As the name suggests, LivePerson (NASDAQ:LPSN) provides online real-time assistance and expert advice. The cloud-based chat company is near its all-time highs after its CEO in May said that it expects to end the year with an annual revenue run rate of around 20%. Shares are now up 73% year-to-date.Going forward, analysts are firmly bullish about LivePerson's outlook. Many analysts have published "buy" ratings on the stock this year, including (five-star Oppenheimer analyst Koji Ikeda. * The 10 Best Stocks to Invest in for August "We believe LivePerson is well positioned to take share in a large B2C messaging opportunity that is disrupting the contact center" writes Ikeda. "Organizations around the world are under pressure to rethink and retool legacy technologies with next-generation customer engagement applications, like LivePerson, to better engage, retain, and generate revenue from the end-consumer" the analyst explains.He believes that over time, good execution in quarterly results and improving business fundamentals should narrow the valuation gap between LPSN and the SaaS Industry average. That makes it a great strong buy stock. Get the LPSN Stock Research Report. Cubic Corp (CUB)Despite Brexit concerns and increasing volatility, growth remains par for the course for Irish defense contractor Cubic Corp (NYSE:CUB).The company has three key business divisions. For investors, it is the company's flagship Cubic Transportation Systems unit that is worth keeping an eye on. According to the company, this is the division responsible for "automated fare payment, traffic management and enforcement solutions."Indeed, transport systems revenue was up 24% year over year, according to CUB's Q1 earnings report. Consequently, Citigroup's Jonathan Raviv cited recent wins- especially in transport- as behind his bullish take on the stock.Meanwhile, Drexel Hamilton's David Williams wrote: "We remain positive on CUB and expect further acquisitions to supplement top and bottom-line growth, which is likely to drive short term upside to expectations, and provide a strong long-term growth trajectory."As such, the analyst reiterates his "buy" rating and $85 price target (38% upside potential) on this strong buy stock. Six analysts give the stock a buy rating, while their average price target works out at $76.40. Get the CUB Stock Research Report.TipRanks.com offers exclusive insights for investors by focusing on the moves of experts: Analysts, Insiders, Bloggers, Hedge Fund Managers and more. See what the experts are saying about your stocks now at TipRanks.com. As of this writing, Harriet Lefton did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Reasons Kraft Heinz Stock Is a Contrarian Buy * 5 Housing Stocks to Buy for Renewed Homebuilder Confidence * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio The post 7 Strong Buy Stocks the Street Loves appeared first on InvestorPlace.
- Kiplinger
5 Biotech Stocks to Buy for Blockbuster Potential
Biotechnology has boomed over the past few decades as our understanding of living organisms and the human machine has swelled. As a result, biotech stocks have become some of the most exciting growth plays on Wall Street.And their potential to deliver sky-high returns is especially explosive when they're developing a drug with blockbuster potential.Blockbuster drugs are those popular treatments that generate annual sales of at least $1 billion. They're uncommon: A drug must have the right combination of price and number of potential patients, so only a handful of treatments at any given time even have the potential to become billion-dollar products. And not all of them live up to their potential.So how can you pinpoint biotech stocks with these kind of superstar drugs in the pipeline? We suggest turning to Wall Street's pros.Here are five promising biotech stocks to buy for their blockbuster-drug potential. TipRanks data shows that all five stocks boast a "Strong Buy" consensus among the Wall Street analysts covering them, based on ratings given during the past three months. SEE ALSO: The 20 Best Small-Cap Dividend Stocks to Buy
